Literature DB >> 10987503

Effect of brown spider venom on basement membrane structures.

S S Veiga1, L Feitosa, V L dos Santos, G A de Souza, A S Ribeiro, O C Mangili, M A Porcionatto, H B Nader, C P Dietrich, R R Brentani, W Gremski.   

Abstract

Loxoscelism or necrotic arachnidism are terms used to describe lesions and reactions induced by bites (envenomation) from spiders of the genus Loxosceles. Envenomation has been reported to provoke dermonecrosis and haemorrhage at the bite site and haemolysis, disseminated intravascular coagulation and renal failure. The purpose of this work was to study the effect of the venom of the brown spider Loxosceles intermedia on basement membrane structures and on its major constituent molecules. Light microscopy observations showed that L. intermedia venom obtained through electric shock, which reproduces two major signals of Loxoscelism in the laboratory, exhibits activity toward basement membrane structures in mouse Engelbreth-Holm-Swarm (EHS) sarcoma. Basement degradation was seen by a reduced periodic acid-Schiff (PAS) and alcian blue staining as well as by a reduced immunostaining for laminin when compared to control experiments. Electron microscopy studies confirmed the above results, showing the action of the venom on EHS-basement membranes and demonstrating that these tissue structures are susceptible to the venom. Using purified components of the basement membrane, we determined through SDS-PAGE and agarose gel that the venom is not active toward laminin or type IV collagen, but is capable of cleaving entactin and endothelial heparan sulphate proteoglycan. In addition, when EHS tissue was incubated with venom we detected a release of laminin into the supernatant, corroborating the occurrence of some basement membrane disruption. The venom-degrading effect on entactin was blocked by 1, 10-phenanthroline, but not by other protease inhibitors such as PMSF, NEM or pepstatin-A. By using light microscopy associated with PAS staining we were able to identify that 1,10-phenanthroline also inhibits EHS-basement membrane disruption evoked by venom, corroborating that a metalloprotease of venom is involved in these effects. Degradation of these extracellular matrix molecules and the observed susceptibility of the basement membrane could lead to loss of vessel and glomerular integrity, resulting in haemorrhage and renal problems after envenomation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987503     DOI: 10.1023/a:1004031019827

Source DB:  PubMed          Journal:  Histochem J        ISSN: 0018-2214


  34 in total

1.  Laminin--a glycoprotein from basement membranes.

Authors:  R Timpl; H Rohde; P G Robey; S I Rennard; J M Foidart; G R Martin
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

Review 2.  Loxoscelism.

Authors:  J M Futrell
Journal:  Am J Med Sci       Date:  1992-10       Impact factor: 2.378

3.  HEMOTOXIC EFFECT OF LOXOSCELES RECLUSUS VENOM: IN VIVO AND IN VITRO STUDIES.

Authors:  W F DENNY; C J DILLAHA; P N MORGAN
Journal:  J Lab Clin Med       Date:  1964-08

4.  Hormone and neurotransmitter receptors in an established vascular endothelial cell line.

Authors:  V Buonassisi; J C Venter
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

5.  Physiological action of Loxosceles reclusa (G&M) venom on insect larvae.

Authors:  F M Eskafi; B R Norment
Journal:  Toxicon       Date:  1976       Impact factor: 3.033

6.  Electrophoretic behaviour of acidic mucopolysaccharides in diamine buffers.

Authors:  C P Dietrich; S M Dietrich
Journal:  Anal Biochem       Date:  1976-02       Impact factor: 3.365

7.  Oligosaccharide residues of Loxosceles intermedia (brown spider) venom proteins: dependence on glycosylation for dermonecrotic activity.

Authors:  S S Veiga; W Gremski; V L dos Santos; L Feitosa; O C Mangili; H B Nader; C P Dietrich; R R Brentani
Journal:  Toxicon       Date:  1999-04       Impact factor: 3.033

8.  Dermonecrotic and lethal components of Loxosceles gaucho spider venom.

Authors:  K C Barbaro; J L Cardoso; V R Eickstedt; I Mota
Journal:  Toxicon       Date:  1992-03       Impact factor: 3.033

9.  Immunocytochemical localization of heparan sulphate proteoglycan in the rat submandibular gland.

Authors:  W Gremski; L S Cutler
Journal:  Histochem J       Date:  1991-08

10.  Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV.

Authors:  J W Fox; U Mayer; R Nischt; M Aumailley; D Reinhardt; H Wiedemann; K Mann; R Timpl; T Krieg; J Engel
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

View more
  9 in total

1.  Whole venom of Loxosceles similis activates caspases-3, -6, -7, and -9 in human primary skin fibroblasts.

Authors:  Arthur Estanislau Dantas; Carolina Campolina Rebello Horta; Thais M M Martins; Anderson Oliveira do Carmo; Bárbara Bruna Ribeiro de Oliveira Mendes; Alfredo M Goes; Evanguedes Kalapothakis; Dawidson A Gomes
Journal:  Toxicon       Date:  2014-04-12       Impact factor: 3.033

2.  Identification, cloning, expression and functional characterization of an astacin-like metalloprotease toxin from Loxosceles intermedia (brown spider) venom.

Authors:  Rafael B da Silveira; Ana C M Wille; Olga M Chaim; Marcia H Appel; Dilza T Silva; Célia R C Franco; Leny Toma; Oldemir C Mangili; Waldemiro Gremski; Carl P Dietrich; Helena B Nader; Silvio S Veiga
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

3.  Histopathological findings in rabbits after experimental acute exposure to the Loxosceles intermedia (brown spider) venom.

Authors:  Katia Zoghbi Ospedal; Marcia Helena Appel; José Fillus Neto; Oldemir Carlos Mangili; Silvio Sanches Veiga; Waldemiro Gremski
Journal:  Int J Exp Pathol       Date:  2002-12       Impact factor: 1.925

4.  Factor Xa-like and fibrin(ogen)olytic activities of a serine protease from Hippasa agelenoides spider venom gland extract.

Authors:  S Devaraja; K S Girish; V R Devaraj; K Kemparaju
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

5.  Loxosceles gaucho venom-induced acute kidney injury--in vivo and in vitro studies.

Authors:  Rui V Lucato; Regina C R M Abdulkader; Katia C Barbaro; Glória E Mendes; Isac Castro; Maria A S F Baptista; Patrícia M Cury; Denise M C Malheiros; Nestor Schor; Luis Yu; Emmanuel A Burdmann
Journal:  PLoS Negl Trop Dis       Date:  2011-05-31

Review 6.  Brown spider (Loxosceles genus) venom toxins: tools for biological purposes.

Authors:  Olga Meiri Chaim; Dilza Trevisan-Silva; Daniele Chaves-Moreira; Ana Carolina M Wille; Valéria Pereira Ferrer; Fernando Hitomi Matsubara; Oldemir Carlos Mangili; Rafael Bertoni da Silveira; Luiza Helena Gremski; Waldemiro Gremski; Andrea Senff-Ribeiro; Silvio Sanches Veiga
Journal:  Toxins (Basel)       Date:  2011-03-22       Impact factor: 4.546

7.  Design and Production of a Recombinant Hybrid Toxin to Raise Protective Antibodies Against Loxosceles Spider Venom.

Authors:  Paula A L Calabria; Lhiri Hanna A L Shimokava-Falcao; Monica Colombini; Ana M Moura-da-Silva; Katia C Barbaro; Eliana L Faquim-Mauro; Geraldo S Magalhaes
Journal:  Toxins (Basel)       Date:  2019-02-12       Impact factor: 4.546

Review 8.  Brown Spider (Loxosceles) Venom Toxins as Potential Biotools for the Development of Novel Therapeutics.

Authors:  Daniele Chaves-Moreira; Fernando Hitomi Matsubara; Zelinda Schemczssen-Graeff; Elidiana De Bona; Vanessa Ribeiro Heidemann; Clara Guerra-Duarte; Luiza Helena Gremski; Carlos Chávez-Olórtegui; Andrea Senff-Ribeiro; Olga Meiri Chaim; Raghuvir Krishnaswamy Arni; Silvio Sanches Veiga
Journal:  Toxins (Basel)       Date:  2019-06-19       Impact factor: 4.546

9.  Isolation, N-glycosylations and Function of a Hyaluronidase-Like Enzyme from the Venom of the Spider Cupiennius salei.

Authors:  Olivier Biner; Christian Trachsel; Aline Moser; Lukas Kopp; Nicolas Langenegger; Urs Kämpfer; Christoph von Ballmoos; Wolfgang Nentwig; Stefan Schürch; Johann Schaller; Lucia Kuhn-Nentwig
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.